IBB logo

IBB
iShares Biotechnology ETF

23,572
Volume
542,430.00
52W High
$179.64
52W Low
$119.78
50D MA
$168.88
Prev Close
$169.06
Loading...
Loading...
News
all
press releases
ONC Stock Gains As BeOne Medicines Wins US Nod For BEQALZI In Rare Lymphoma
The FDA approved BEQALZI in the treatment of certain mantle cell lymphoma patients on Wednesday.
News Placeholder
More News
News Placeholder
ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost
On Monday, AbCellera will release its financial results alongside interim early-stage data for its lead internal candidate ABCL635.
News Placeholder
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Smart Beta ETF report for IBB
News Placeholder
CMPS On Track For Best Week Ever On FDA Push For Psychedelics
Compass said on Friday that the FDA has granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.
News Placeholder
KYTX Stock Soars After Hours: What’s Driving The Rally?
Kyverna reported strong pivotal trial results for its one-time CAR-T therapy miv-cel, showing rapid mobility improvements and reversal of disability in patients with stiff person syndrome.
News Placeholder
Should You Invest in the iShares Biotechnology ETF (IBB)?
Sector ETF report for IBB
News Placeholder
LEGN Stock Clocks Best Day In Three Years — What’s Driving The Rally?
After Eli Lilly and Company bought Kelonia to advance CAR-T cell therapies, retail traders are now speculating a buyout for Legend.
News Placeholder
AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug
Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
News Placeholder
AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage
Anavex presented new data from its Phase IIb and Phase III blarcamesine programs, showing that preservation of brain volume is associated with improved patient outcomes.
News Placeholder
The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM
IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available